Rituximab-pvvr (Ruxience) is a "biosimilar" of Rituximab and the LH formulary agent of choice inpatient. Outpatient selection is based on insurance preference/formulary.
For non-oncologic condition, refer to EHR order set IP Non-Onc Rituximab (#2592) for adults or Peds Rituximab Infusion (#1327) for children. (Note: Monoclonal antibodies given for a non-oncologic condition do not require a chemotherapy certified nurse).
For oncologic condition, refer to the EHR order set IP Onc Rituximab (#1935) or the appropriate order set that contains rituximab as part of the chemotherapy protocol. (NOTE: Monoclonal antibodies given as part of a chemotherapy protocol will be given by a chemotherapy certified RN.)
Administration and Handling of antineoplastic drugs: Policy 906.4802
May be given via hypodermoclysis (HDC/subcutaneous infusion). See Procedure 904.4991
Add Formweb to your mobile device
Rituximab-pvvr (Ruxience) is a "biosimilar" of Rituximab and the LH formulary agent of choice inpatient. Outpatient selection is based on insurance preference/formulary.
For non-oncologic condition, refer to EHR order set IP Non-Onc Rituximab (#2592) for adults or Peds Rituximab Infusion (#1327) for children.
(Note: Monoclonal antibodies given for a non-oncologic condition do not require a chemotherapy certified nurse).
For oncologic condition, refer to the EHR order set IP Onc Rituximab (#1935) or the appropriate order set that contains rituximab as part of the chemotherapy protocol.
(NOTE: Monoclonal antibodies given as part of a chemotherapy protocol will be given by a chemotherapy certified RN.)
Administration and Handling of antineoplastic drugs: Policy 906.4802
May be given via hypodermoclysis (HDC/subcutaneous infusion). See Procedure 904.4991
Rituximab may only be ordered via Order Set. See 900.3233 Medications: Orders